Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)

Spinocerebellar Ataxia Type 2 Clinical Trial

— ATRIL  

Official title:

Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03347344
• Other study ID #: P160927J
• Secondary ID: 2017-001481-23
• Status: Completed
• Phase: Phase 3
• Start date: January 17, 2018
• Est. completion date: December 14, 2020

Study information

• Verified date: June 2021
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ATRIL is a multi-centric, double-blind randomized, two-arm controlled study. 42 SpinoCerebellar Ataxia type 2 (SCA2) patients, both gender, at least 18 years of age will be included.

Riluzole 50 mg will be administered (per os) twice a day, versus one group with placebo for 12 months.

Riluzole (Rilutek®) is a benzothiazole drug, market approved, for Amyotrophic Lateral Sclerosis (ALS). It delays the onset of ventilator-dependence or tracheostomy in selected patients and may increase survival.

Scale for the Assessment and Rating of Ataxia (SARA) will be used at M0, M6 and M12. To assess primary criterion, the percentage of patients with a decrease of at least 1 point of the SARA score between the inclusion visit, and Visit 3 (Months 12) will be calculated.

Description:

Inherited cerebellar ataxias are genetically heterogeneous neurological disorders. They are characterized by ataxic gait and cerebellar dysarthria that progresses over time with loss of ambulation and speech. The mutations by expansions of CAG triplets in the genes ATXN1 (SCA1), ATXN 2 (SCA2), 3 (SCA3), CACNA1A (SCA6), ATXN 7 (SCA7), and TBP (SCA17) are responsible for 50% of hereditary forms There is no curative or preventive treatment. This phase III study is a multi-centric, double-blind randomized, two-arm controlled study (one group with 50 mg Riluzole twice a day versus one group with placebo), to measure the efficacy of treatment with riluzole in SCA2 patients during 12 months. Amelioration is defined by a 1 point decrease of the SARA score.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: December 14, 2020
• Est. primary completion date: December 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Genetically diagnosed SCA2 (CAG triplet in ATXN2 = 33)

• At least 18 years of age

• Signature of informed consent

• Covered by social security

• SARA score = 5 and = 26

• Age at onset = 50 years old

Exclusion Criteria:

• Treated with riluzole prior to the study

• Hepatotoxic medication

• Hypersensitivity to the active substance or to any of the excipients

• Serious systemic illnesses or conditions known for enhancing the side effects of riluzole

• Contraindications for MRI examination

• Participation in another therapeutic trial (3 months exclusion period)

• Pregnancy or breastfeeding

• Non abstinence or absence of effective contraception for women

• Inability to understand information about the protocol

• Persons deprived of their liberty by judicial or administrative decision

• Adult subject under legal protection or unable to consent

• Other ataxic syndromes than SCA2

Related Conditions & MeSH terms

• Ataxia
• Cerebellar Ataxia
• Spinocerebellar Ataxia Type 2
• Spinocerebellar Ataxias
• Spinocerebellar Degenerations

Intervention

Drug:
• Riluzole
50 mg will be administered (per os) twice a day
• Placebo
50 mg will be administered (per os) twice a day

Locations

Country	Name	City	State
France	Durr	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Ataxia symptoms (Scale for the Assessment and Rating of Ataxia (SARA))	To compare the proportion of patients with Scale for the Assessment and Rating of Ataxia (SARA) improvement (decrease) of at least one point from baseline to 12 months	at 12 months.
Secondary	Change in Ataxia symptoms (Composite Cerebellar Functional Severity (CCFS) score)	To compare the difference of the CCFS score (Composite Cerebellar Functional Severity Score) from baseline at 12 months. A decrease is expected in the intervention group.	at 12 months
Secondary	Change in extracerebellar symptoms (Inventory of Non-Ataxia Signs (INAS))	To compare the difference of the extracerebellar symptoms (INAS, Inventory of Non-Ataxia Signs) by showing decrease in the INAS count from baseline at 12 months	at 12 months
Secondary	12 months survival	To compare survival of the patients between the two treatment groups at 12 months	at 12 months